How do clinical outcomes compare between relugolix monotherapy and combination therapy?

Label:chem

Topic
The LIBERTY trials included arms of continuous combination therapy, delayed add-back (12 weeks monotherapy then 12 weeks combination), and placebo.
Answer
Continuous combination therapy rapidly reduced HMB, improved anemia, and minimized vasomotor adverse events while preserving BMD. Delayed add-back halted further BMD decline after initial loss but did not restore lost bone; hot-flush incidence was 2–3-fold higher during the monotherapy lead-in versus continuous combination therapy.
Return to Home Chemical List
Knowledge you may be interested in
Does relugolix combination therapy preserve BMD over extended treatment periods? What strategy has been developed to mitigate relugolix-induced BMD loss? How does relugolix monotherapy affect bone mineral density (BMD)? What is relugolix, and how does it function as a therapeutic agent in uterine diseases? Does combining diazepam with low-frequency rTMS produce additive or synergistic suppression of Ca²⁺ elevation? What is diazepam’s pharmacological role in modulating epileptiform activity, and at what concentration was it tested? What is ferric derisomaltose (FDI), and what is its chemical role in research study? What are the molecular mechanisms by which vitamin D affects muscle health? How does vitamin D deficiency contribute to sarcopenia? What is the role of vitamin D (Vit D) in skeletal muscle physiology? What evidence supports the efficacy of relugolix combination therapy in endometriosis? What role does desloratadine or levocetirizine play when added to oral isotretinoin in the treatment of acne vulgaris? How do zinc ions affect influenza A virus (IAV) hemagglutinin function and virus infectivity? Does zinc-mediated inactivation compromise the structural integrity of the IAV particle? Is the antiviral activity of zinc ions maintained across physiologically relevant temperatures? What is Cucurbitacin E (CuE) and where is it derived from? Does Cucurbitacin E (CuE) exhibit cytotoxicity toward 3T3-L1 adipocytes during adipogenesis? How does CuE influence lipid accumulation in differentiating 3T3-L1 adipocytes? Which key adipogenic transcription factors are down-regulated by Cucurbitacin E (CuE)? What molecular pathways are implicated in CuE-mediated inhibition of adipogenesis and lipogenesis?